Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents



Status:Recruiting
Conditions:Ovarian Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 127
Updated:3/7/2019
Start Date:October 21, 2014
End Date:April 21, 2021
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.

This is a modular, phase I/ phase 1 b, open-label, multicentre study of AZD6738 administered
orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents,
to patients with advanced malignancies. The study design allows an investigation of optimal
combination dose of AZD6738 with other anti-cancer treatments, with intensive safety
monitoring to ensure the safety of the patients. The initial combination to be investigated
is AZD6738 with carboplatin. The second combination to be investigated is AZD6738 with
Olaparib. The third combination to be investigated is AZD6738 with MEDI4736.

This is a modular, phase I, 2 part, open-label, multicentre study of AZD6738, administered
orally, in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents,
to patients with advanced/metastatic solid malignancies. The study design allows an
escalation of the dose of AZD6738 in combination with the standard dose and schedule of
either cytotoxic chemotherapies and/or novel anti-cancer agents, with intensive safety
monitoring to ensure the safety of the patients. There are two parts to each combination
module of this study; part A, dose escalation and an optional part B, cohort expansions in
particular patient groups. The initial combination module will be with Carboplatin (module
1). The second combination will be with Olaparib (module 2). The third combination will be
with MEDI4736 (module 3). The option to start further combination modules will be the
decision of the Safety Review Committee (SRC), based on emerging preclinical data and, safety
and tolerability information from the initial combination. Combinations of AZD6738 with novel
anti-cancer agents may also be explored. Once a minimally biologically active dose of
AZD6738, for that combination module, has been identified from part A of that module, the SRC
may decide to commence part B if deemed to be necessary. This may include cohort expansions
of specific patient groups to explore preliminary anti-tumour activity or the effect of food
or particular drug combinations on drug pharmacokinetics.

Principal Inclusion criteria:

- Aged at least 18

- The presence of a solid malignant tumour that is not considered appropriate for
further standard treatment

- Module 1 and 2 Part B study expansions, and Module 3: patients must have a tumour at
least 1 cm in size that can be measured using a CT or MRI scan

- Module 1 Part B Study expansion: second line lung adenocarcinoma with ATM deficient
tumours.

- Module 2 Part B All - No previous treatment with PARP inhibitor.

- Module 2 Part B1 Study expansion: advanced gastric adenocarcinoma (including GEJ)
patients with ATM deficient tumours

- Module 2 Part B2 Study expansion: advanced gastric adenocarcinoma (including GEJ)
patients with ATM proficient tumours

- Module2 Part B3 Study expansion: Second or thrid line HER2 negative breast cancer

- Module 2 Part B4 Study expansion: Second or third line triple negative breast cancer
(TNBC) Module 3: advanced recurrent or metastatic non-small cell lung cancer, or head
and neck squamous cell carcinoma

Principal exclusion criteria

- A diagnosis of ataxia telangiectasia

- Prior exposure to an ATR inhibitor

- Bad reaction to AZD6738

- Module 1: Contra-indicated for treatment with carboplatin

- Module 2: Contra-indicated for treatment with olaparib

- Module 3: Contra-indicated for treatment with MEDI4736
We found this trial at
7
sites
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
MARSEILLE Cedex 5,
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Newport Beach, California 92660
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials